Hyperamylasaemia in asymptomatic HIV patients

Area of Science:

• Clinical Biochemistry
• Infectious Diseases
• Gastroenterology

Background:

• Human Immunodeficiency Virus (HIV) infection can impact various physiological systems.
• Elevated serum amylase levels (hyperamylasemia) can indicate pancreatic dysfunction but may have other causes.
• Dideoxyinosine (DDI) is an antiretroviral drug known to be associated with pancreatitis.

Purpose of the Study:

• To prospectively investigate the prevalence and causes of asymptomatic hyperamylasemia in HIV-infected patients.
• To determine the specific isoenzyme patterns (pancreatic, salivary, macroamylase) contributing to elevated serum amylase in this population.
• To assess the association between DDI use and hyperamylasemia in HIV patients.

Main Methods:

• Prospective study of 163 asymptomatic HIV-infected patients attending an outpatient clinic.
• Measurement of serum total amylase and its isoenzymes (pancreatic and salivary).
• Detection of macroamylase and correlation with clinical data, including DDI use.

Main Results:

• 24% of HIV patients (39/163) exhibited asymptomatic hyperamylasemia.
• Elevations were attributed to pancreatic isoamylase alone (28%), salivary isoamylase alone (42%), or both (17%).
• Macromylase was detected in 13% (5/163) of patients, a higher incidence than typically observed. Four of six DDI-treated patients had elevated pancreatic amylase, and two had macroamylase.

Conclusions:

• Asymptomatic hyperamylasemia is a frequent finding in HIV patients.
• The causes of hyperamylasemia in this cohort are diverse, including pancreatic, salivary, and macroamylase.
• The high prevalence of macroamylasemia in HIV patients, particularly those on DDI, warrants further investigation.